Patents by Inventor Justin Du Bois
Justin Du Bois has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11834456Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.Type: GrantFiled: January 26, 2022Date of Patent: December 5, 2023Assignees: SITEONE THERAPEUTICS, INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: John Mulcahy, Hassan Pajouhesh, George Miljanich, Anton Delwig, Jacob Beckley, Grant Masaaki Shibuya, Justin Du Bois
-
Publication number: 20220259218Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.Type: ApplicationFiled: January 26, 2022Publication date: August 18, 2022Inventors: John Mulcahy, Hassan Pajouhesh, George Miljanich, Anton Delwig, Jacob Beckley, Grant Masaaki Shibuya, Justin Du Bois
-
Patent number: 11279706Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R1, X1, and X2 are as described herein.Type: GrantFiled: March 29, 2018Date of Patent: March 22, 2022Assignees: SITEONE THERAPEUTICS, INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: John Mulcahy, Hassan Pajouhesh, George Miljanich, Anton Delwig, Jacob Beckley, Grant Masaaki Shibuya, Justin Du Bois
-
Patent number: 11236097Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.Type: GrantFiled: March 29, 2018Date of Patent: February 1, 2022Assignees: SITEONE THERAPEUTICS, INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: John Mulcahy, Hassan Pajouhesh, George Miljanich, Anton Delwig, Jacob Beckley, Grant Masaaki Shibuya, Justin Du Bois
-
Patent number: 11173137Abstract: Provided herein are small-molecules for use in modulating chloride ion channel (CLC) activity, particularly the activity of CLC-2, to elucidate the role of CLC-2 in disorders associated with CLC-2 malfunction, and to identify therapeutic leads for their treatment. Compositions and methods for modulating CLC activity are also provided. In certain aspects, the subject compounds and compositions are useful for imaging or channel pull-down studies.Type: GrantFiled: June 21, 2019Date of Patent: November 16, 2021Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Anna K. Koster, Justin Du Bois, Merritt C. Maduke
-
Publication number: 20200102318Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.Type: ApplicationFiled: March 29, 2018Publication date: April 2, 2020Inventors: John MULCAHY, Hassan PAJOUHESH, George MILJANICH, Anton DELWIG, Jacob BECKLEY, Grant Masaaki SHIBUYA, Justin DU BOIS
-
Publication number: 20200102317Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R1, X1, and X2 are as described herein.Type: ApplicationFiled: March 29, 2018Publication date: April 2, 2020Inventors: John MULCAHY, Hassan PAJOUHESH, George MILJANICH, Anton DELWIG, Jacob BECKLEY, Grant Masaaki SHIBUYA, Justin DU BOIS
-
Publication number: 20200016103Abstract: Provided herein are small-molecules for use in modulating chloride ion channel (CLC) activity, particularly the activity of CLC-2, to elucidate the role of CLC-2 in disorders associated with CLC-2 malfunction, and to identify therapeutic leads for their treatment. Compositions and methods for modulating CLC activity are also provided. In certain aspects, the subject compounds and compositions are useful for imaging or channel pull-down studies.Type: ApplicationFiled: June 21, 2019Publication date: January 16, 2020Inventors: Anna K. Koster, Justin Du Bois, Merritt C. Maduke
-
Patent number: 10513525Abstract: Saxitoxin analogue compounds, compositions, pharmaceutical compositions, methods of synthesis of saxitoxin analogues, methods of imaging, methods of treatment, including methods of treating pain, are provided. Saxitoxin (STX), gonyautoxin (GTX), and zetekitoxin, and variant STX compounds bind to sodium channels and are effective to reduce or block flow of sodium ions through such channels. Such channel block affects nerve and muscle action, and may be effective to reduce or block pain sensations, relax muscles, reduce muscle spasm, and reduce wrinkles. STX analogue binding to sodium channels may also be useful to locate, image, or mark sodium channels, and so be useful in studying sodium channels and sodium channel disorders, and in the diagnosis and treatment of patients suffering from sodium channel disorders. In embodiments, the variant STX compounds include conjugates having increased serum half-life as compared to STX when administered to a subject.Type: GrantFiled: October 26, 2015Date of Patent: December 24, 2019Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Justin Du Bois, John Mulcahy, Brian Andresen, David C. Yeomans, Sandip Biswal
-
Patent number: 10112953Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R1, X1 and X3 are as described herein.Type: GrantFiled: September 30, 2016Date of Patent: October 30, 2018Assignees: SITEONE THERAPEUTICS, INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: John Mulcahy, Hassan Pajouhesh, Grant Masaaki Shibuya, Anton Delwig, George Miljanich, Justin Du Bois
-
Patent number: 10106549Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function, for example conditions associated with pain. The compounds are 10?,11?-modified saxitoxins. The compounds are optionally additionally modified at carbon 13. In certain embodiments, the 10?,11?-modified saxitoxins are of Formula I: where R1, R2 and R3 are as described herein. Also provided herein are methods of treating pain in a mammal comprising administering an effective treatment amount of a 10?,11? modified saxitoxin or composition to a mammal. In an embodiment, the mammal is a human.Type: GrantFiled: April 9, 2015Date of Patent: October 23, 2018Assignees: SITEONE THERAPEUTICS, INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Hassan Pajouhesh, George Miljanich, John Mulcahy, Justin Du Bois, Matthew Axtman, James Walker, Jeffrey E. Merit
-
Publication number: 20170233398Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R1, X1 and X3 are as described herein.Type: ApplicationFiled: September 30, 2016Publication date: August 17, 2017Inventors: John MULCAHY, Hassan PAJOUHESH, Grant Masaaki SHIBUYA, Anton DELWIG, George MILJANICH, Justin DU BOIS
-
Publication number: 20170029431Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function, for example conditions associated with pain. The compounds are 10?,11?-modified saxitoxins. The compounds are optionally additionally modified at carbon 13. In certain embodiments, the 10?,11?-modified saxitoxins are of Formula I: where R1, R2 and R3 are as described herein. Also provided herein are methods of treating pain in a mammal comprising administering an effective treatment amount of a 10?,11? modified saxitoxin or composition to a mammal. In an embodiment, the mammal is a human.Type: ApplicationFiled: April 9, 2015Publication date: February 2, 2017Inventors: Hassan PAJOUHESH, George MILJANICH, John MULCAHY, Justin DU BOIS, Matthew AXTMAN, James WALKER, Jeffrey E. MERIT
-
Publication number: 20160115173Abstract: Saxitoxin analogue compounds, compositions, pharmaceutical compositions, methods of synthesis of saxitoxin analogues, methods of imaging, methods of treatment, including methods of treating pain, are provided. Saxitoxin (STX), gonyautoxin (GTX), and zetekitoxin, and variant STX compounds bind to sodium channels and are effective to reduce or block flow of sodium ions through such channels. Such channel block affects nerve and muscle action, and may be effective to reduce or block pain sensations, relax muscles, reduce muscle spasm, and reduce wrinkles. STX analogue binding to sodium channels may also be useful to locate, image, or mark sodium channels, and so be useful in studying sodium channels and sodium channel disorders, and in the diagnosis and treatment of patients suffering from sodium channel disorders. In embodiments, the variant STX compounds include conjugates having increased serum half-life as compared to STX when administered to a subject.Type: ApplicationFiled: October 26, 2015Publication date: April 28, 2016Inventors: Justin DU BOIS, John MULCAHY, Brian ANDRESEN, David C. YEOMANS, Sandip BISWAL
-
Patent number: 9174999Abstract: Saxitoxin analog compounds, compositions, pharmaceutical compositions, methods of synthesis of saxitoxin analogs, methods of imaging, methods of treatment, including methods of treating pain, are provided. Saxitoxin (STX), gonyautoxin (GTX), and zetekitoxin, and variant STX compounds bind to sodium channels and are effective to reduce or block flow of sodium ions through such channels. Such channel block affects nerve and muscle action, and may be effective to reduce or block pain sensations, relax muscles, reduce muscle spasm, and reduce wrinkles. STX analog binding to sodium channels may also be useful to locate, image, or mark sodium channels, and so be useful in studying sodium channels and sodium channel disorders, and in the diagnosis and treatment of patients suffering from sodium channel disorders. In embodiments, the variant STX compounds include conjugates having increased serum half-life as compared to STX when administered to a subject.Type: GrantFiled: May 7, 2010Date of Patent: November 3, 2015Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Justin Du Bois, John Mulcahy, Brian Andresen, David C. Yeomans, Sandip Biswal
-
Patent number: 9090627Abstract: Compounds relating to batrachotoxin are provided, in particular analogs that modulate the activity of sodium channels. Also provided are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier, including vehicles that modulate transdermal permeation of the compound. The subject compounds are useful in treatments, including treatments to reduce neuronal activity or to bring about muscular relaxation. The compounds also find use in the treatment of subjects suffering from a voltage-gated sodium channel-enhanced ailment or from pain. Further methods are provided for the preparation of the batrachotoxin-related compounds.Type: GrantFiled: December 13, 2013Date of Patent: July 28, 2015Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Justin Du Bois, Abigail Sloan Devlin, Matthew M. Logan, Frederic Menard, Tatsuya Toma
-
Patent number: 9085536Abstract: Compound derivatives of aconitine are provided, in particular derivatives that modulate the activity of sodium channels. Also provided are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier. The subject compounds are useful in treatments, including treatments to modulate neuronal activity or to bring about muscular relaxation. The compounds also find use in the treatment of subjects suffering from a voltage-gated sodium channel-enhanced ailment or from pain. Further methods are provided for the preparation of the aconitine derivatives.Type: GrantFiled: March 15, 2012Date of Patent: July 21, 2015Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Justin Du Bois, Brian M. Andresen, Frederic Menard, Andrew W. Patterson
-
Publication number: 20140171410Abstract: Compounds relating to batrachotoxin are provided, in particular analogues that modulate the activity of sodium channels. Also provided are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier, including vehicles that modulate transdermal permeation of the compound. The subject compounds are useful in treatments, including treatments to reduce neuronal activity or to bring about muscular relaxation. The compounds also find use in the treatment of subjects suffering from a voltage-gated sodium channel-enhanced ailment or from pain. Further methods are provided for the preparation of the batrachotoxin-related compounds.Type: ApplicationFiled: December 13, 2013Publication date: June 19, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Justin Du Bois, Abigail Sloan Devlin, Matthew M. Logan, Frederic Menard, Tatsuya Toma
-
Publication number: 20120238526Abstract: Compound derivatives of aconitine are provided, in particular derivatives that modulate the activity of sodium channels. Also provided are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier. The subject compounds are useful in treatments, including treatments to modulate neuronal activity or to bring about muscular relaxation. The compounds also find use in the treatment of subjects suffering from a voltage-gated sodium channel-enhanced ailment or from pain. Further methods are provided for the preparation of the aconitine derivatives.Type: ApplicationFiled: March 15, 2012Publication date: September 20, 2012Inventors: Justin Du Bois, Brian M. Andresen, Frederic Menard
-
Publication number: 20100284913Abstract: Saxitoxin analogue compounds, compositions, pharmaceutical compositions, methods of synthesis of saxitoxin analogues, methods of imaging, methods of treatment, including methods of treating pain, are provided. Saxitoxin (STX), gonyautoxin (GTX), and zetekitoxin, and variant STX compounds bind to sodium channels and are effective to reduce or block flow of sodium ions through such channels. Such channel block affects nerve and muscle action, and may be effective to reduce or block pain sensations, relax muscles, reduce muscle spasm, and reduce wrinkles. STX analogue binding to sodium channels may also be useful to locate, image, or mark sodium channels, and so be useful in studying sodium channels and sodium channel disorders, and in the diagnosis and treatment of patients suffering from sodium channel disorders. In embodiments, the variant STX compounds include conjugates having increased serum half-life as compared to STX when administered to a subject.Type: ApplicationFiled: May 7, 2010Publication date: November 11, 2010Applicant: The Board of Trustees of the Leland Stanford JunioInventors: Justin Du Bois, John Mulcahy, Brian Andresen, David C. Yeomans, Sandip Biswal